A practical and evidence-based approach to cardiovascular disease risk reduction

被引：46

作者：

Gluckman, TJ ^{[1
]}

Baranowski, B ^{[1
]}

Ashen, D ^{[1
]}

Henrikson, CA ^{[1
]}

McAllister, M ^{[1
]}

Braunstein, JB ^{[1
]}

Blumenthal, RS ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Med, Cardiol Div,Ciccarone Prevent Cardiol Ctr, Baltimore, MD 21205 USA

来源：

ARCHIVES OF INTERNAL MEDICINE | 2004年 / 164卷 / 14期

关键词：

D O I：

10.1001/archinte.164.14.1490

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Implementation of the numerous lifestyle and medical management options for secondary prevention of cardiovascular disease remains a daunting goal for primary care physicians and cardiologists alike. Despite the existence of expert consensus guidelines on cardiovascular prevention by the American College of Cardiology and the American Heart Association, therapies known to improve patient care and decrease morbidity and mortality remain underutilized. This, review attempts to simplify cardiovascular risk reduction by summarizing key clinical trials in an "ABC" format. We believe that if health care providers and patients use such a format, important lifestyle and pharmacologic options will more likely be addressed.

引用

页码：1490 / 1500

页数：11

共 141 条

[11]

[Anonymous], 1997, WHO TECHN REP SER

[12]

[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]

[13]

[Anonymous], 2003, NAT DIAB FACT SHEET

[14]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[15]

BALL SG, 1993, LANCET, V342, P821

[16]

Black HR, 1997, ARCH INTERN MED, V157, P2413

[17] β-adrenergic blocking agents in heart failure -: Benefits of vasodilating and nonvasodilating agents according to patients' characteristics:: A meta-analyis of clinical trials [J].

Bonet, S ;

Agusti, A ;

Arnau, JM ;

Vidal, X ;

Diogène, E ;

Galve, E ;

Laporte, JR .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :621-627

[18]

Braunstein J B, 2001, Cardiol Rev, V9, P96, DOI 10.1097/00045415-200103000-00008

[19] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[20]

*BRIST MYERS SQUIB, PRAV PAC PRESS REL N

← 1 2 3 4 5 6 7 8 9 10 →